Carregant...
First Allogeneic CAR T‐Cell Therapy Impresses in Relapsed/Refractory Lymphoma
In the phase I ALPHA trial, the first allogeneic “off‐the‐shelf” CAR T‐cell therapy regimen showed clinical benefits in patients with relapsed/refractory large B‐cell or follicular lymphoma.
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Inc.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7330918/ https://ncbi.nlm.nih.gov/pubmed/32588932 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0570 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|